A
14.30
-0.20 (-1.38%)
| Penutupan Terdahulu | 14.50 |
| Buka | 14.41 |
| Jumlah Dagangan | 1,305,000 |
| Purata Dagangan (3B) | 3,904,115 |
| Modal Pasaran | 9,434,472,448 |
| Harga / Pendapatan (P/E TTM) | 57.20 |
| Harga / Jualan (P/S) | 13.39 |
| Harga / Buku (P/B) | 3.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Mar 2025 |
| Margin Keuntungan | 5.62% |
| Margin Operasi (TTM) | -3,921.72% |
| EPS Cair (TTM) | 0.040 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2,509.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.24% |
| Nisbah Semasa (MRQ) | 14.92 |
| Aliran Tunai Operasi (OCF TTM) | -12.92 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 73.63 M |
| Pulangan Atas Aset (ROA TTM) | -0.64% |
| Pulangan Atas Ekuiti (ROE TTM) | 1.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ABBISKO-B | - | - |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ABBISKO-B | 9 B | - | 57.20 | 3.83 |
| ALPHAMAB-B | 10 B | - | 41.23 | 5.23 |
| LEPU BIO-B | 10 B | - | - | 12.92 |
| CSTONE PHARMA-B | 9 B | - | - | 23.87 |
| FRONTAGE | 2 B | - | 104.00 | 0.790 |
| GENOR-B | 2 B | - | 54.43 | 1.47 |
|
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 20.60% |
| % Dimiliki oleh Institusi | 22.45% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |